These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2297589)

  • 1. Failure of anti-MHC antibodies to prevent GVHD in DLA mismatched unrelated canine marrow recipients.
    Ladiges WC; Storb R; Raff RF; Appelbaum FR; Sandmaier B; Schuening F; Graham T
    Bone Marrow Transplant; 1990 Jan; 5(1):43-6. PubMed ID: 2297589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Resistance' to unrelated, DLA-nonidentical canine marrow grafts is unrestricted by the major histocompatibility complex.
    Raff RF; Sandmaier BM; Graham T; Loughran TP; Pettinger M; Storb R
    Exp Hematol; 1994 Aug; 22(9):893-7. PubMed ID: 8062888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion.
    Zorn J; Herber M; Schwamberger S; Panzer W; Adler H; Kolb HJ
    Exp Hematol; 2009 Aug; 37(8):998-1006. PubMed ID: 19446000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA; Schmidberger H; Buchsbaum DJ; Everson P; Snover DC; Blazar BR
    Cancer Res; 1991 Apr; 51(7):1891-7. PubMed ID: 2004372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-versus-host disease after marrow transplantation.
    Storb R
    Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recipient-specific donor cytotoxic T lymphocytes enhance engraftment of unrelated, DLA non-identical canine marrow.
    Schwarzinger I; Raff RF; Flowers M; Niederwieser D; Graham T; Shulman H; Appelbaum FR; Schuening F; Storb R
    Bone Marrow Transplant; 1994 Mar; 13(3):303-9. PubMed ID: 8199572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation.
    Yu C; Storb R; Deeg HJ; Graham TC; Scheuning FG; Huss R; Seidel K; Fitzsimmons WE
    Bone Marrow Transplant; 1996 Apr; 17(4):649-53. PubMed ID: 8722370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
    J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow.
    Storb R; Kolb HJ; Deeg HJ; Weiden PL; Appelbaum F; Graham TC; Thomas ED
    Bone Marrow Transplant; 1986 Dec; 1(2):167-77. PubMed ID: 3332131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-phase pathogenesis of graft-versus-host disease in mice.
    van Leeuwen L; Guiffre A; Atkinson K; Rainer SP; Sewell WA
    Bone Marrow Transplant; 2002 Jan; 29(2):151-8. PubMed ID: 11850710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.
    Mutis T; Gillespie G; Schrama E; Falkenburg JH; Moss P; Goulmy E
    Nat Med; 1999 Jul; 5(7):839-42. PubMed ID: 10395333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoids fail to enhance the effect of FK506 and methotrexate in prevention of graft-versus-host disease after DLA-nonidentical, unrelated marrow transplantation.
    Yu C; Seidel K; Fitzsimmons WE; Sale G; Storb R
    Bone Marrow Transplant; 1997 Jul; 20(2):137-41. PubMed ID: 9244417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow transplantation in miniature swine. III. Graft-versus-host disease and the effect of T cell depletion of marrow.
    Sakamoto K; Sachs DH; Shimada S; Popitz-Bergez FA; Pennington LR; Pescovitz MD; McDonough MA; MacVittie TJ; Katz SI; Gress RE
    Transplantation; 1988 May; 45(5):869-75. PubMed ID: 3285532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.